Lyell Immunopharma, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
LYEL$16.75+8.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders Equity
(in thousands)
| Three Months Ended March 31, 2026 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
| Shares · Amount | ||||||
| Balance as of December 31, 2025 | 21,251 | $2 | $1,867,512 | $242 | $(1,619,554) | $248,202 |
| Issuance of common stock upon exercise of stock options | 3 | — | 26 | — | — | 26 |
| Issuance of common stock in connection with restricted stock units, net of tax | 57 | — | — | — | — | — |
| Issuance of common stock in connection with PIPE financing | 1,952 | — | 43,850 | — | — | 43,850 |
| Issuance of common stock in connection with ATM financing | 65 | — | 1,696 | — | — | 1,696 |
| Stock-based compensation | — | — | 4,295 | — | — | 4,295 |
| Other comprehensive loss | — | — | — | (251) | — | (251) |
| Net loss | — | — | — | — | (24,153) | (24,153) |
| Balance as of March 31, 2026 | 23,328 | $2 | $1,917,379 | $(9) | $(1,643,707) | $273,665 |
| Three Months Ended March 31, 2025 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | ||||||
| Shares · Amount | ||||||
| Balance as of December 31, 2024(1) | 14,744 | $1 | $1,727,638 | $291 | $(1,345,106) | $382,824 |
| Issuance of common stock in connection with restricted stock units, net of tax | 20 | — | 1 | — | — | 1 |
| Stock-based compensation | — | — | 6,024 | — | — | 6,024 |
| Other comprehensive loss | — | — | — | (133) | — | (133) |
| Net loss | — | — | — | — | (52,195) | (52,195) |
| Balance as of March 31, 2025 | 14,764 | $1 | $1,733,663 | $158 | $(1,397,301) | $336,521 |
- Amounts previously reported for common stock and additional paid-in capital have been retroactively adjusted to reflect the 1-for-20 reverse stock split effected on May 30, 2025. See Note 2.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.